Women’s Health Update | Summer 2026

Alantra’s Women’s Health Update | Summer 2026 highlights key trends shaping women’s health within consumer healthcare, including increasing consumer awareness, condition-specific innovation, and continued strategic interest from both established companies and emerging brands.

The update also features insights from Alantra’s recent advisory role on the sale of OrganiCare, owner of FemiClear, to Venture Life Group, a transaction that reflects several broader market dynamics across intimate health and targeted OTC solutions.

Key takeaways from the update:

• Consumer preferences are shifting toward condition-specific, science-backed women’s health solutions, particularly across intimate health, fertility, menopause, hormonal wellness, and nutrition.
• Women’s intimate health remains a significant consumer healthcare category, with the U.S. feminine treatment market exceeding $700mn and the itch & yeast segment representing 46% of feminine treatment sales.
• FemiClear operates in the approximately $321mn U.S. itch & yeast treatment segment, the largest subcategory within feminine treatments, and has delivered double-digit sales growth while many larger competitors have declined.
• Differentiated women’s health brands continue to attract strategic interest, particularly those combining targeted product positioning, natural formulations, clinical credibility, and strong consumer engagement.
• The update highlights selected innovators across the category, including companies focused on fertility and hormone monitoring, vaginal microbiome health, maternal nutrition, menopause, reproductive care, and broader women’s wellness.

Download the full update below